| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Pharvaris N.V.'s insiders have reduced their positions by a net 559,502 shares worth roughly $20.4M.
Classified under Biotechnology (Healthcare sector), PHVS's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 650.0K | $22.75M | - | |
| Dir | 115.2K | $4.17M | - | |
| CFO | 113.8K | - | - | |
| Pres | 110.0K | $3.42M | - | |
| Other | 74.0K | $2.83M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Lu Peng | Chief Medical Officer | Sale+OE10b5-1 | 7,101 | $30.05 | $213,404.75 | -9.7% | +25.9% | - | |
| Apr 16, 2026 | Modig Berndt | Chief Executive Officer | Sell10b5-1 | 2,292 | $28.60 | $65,558.53 | -1.6% | +22.2% | - | |
| Apr 9, 2026 | Modig Berndt | Chief Executive Officer | Sell10b5-1 | 23,333 | $27.74 | $647,281.38 | -14.1% | +32.7% | - |